- Home
- CYH vs CRMD Comparison
CYH vs CRMD Comparison
Compare CYH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | CRMD |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 605.9M |
| IPO Year | 2000 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CYH | CRMD |
|---|---|---|
| Price | $3.46 | $7.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $3.57 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 05-19-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 67.03 |
| EPS | ★ 3.77 | 1.97 |
| Revenue | ★ $12,485,000,000.00 | $43,472,170.00 |
| Revenue This Year | $2.11 | $627.64 |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | ★ $0.97 | $3.75 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $2.24 | $5.60 |
| 52 Week High | $4.43 | $17.43 |
Technical Indicators
Market Signals| Indicator | CYH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.91 | 39.68 |
| Support Level | $2.99 | $6.55 |
| Resistance Level | $3.60 | $8.53 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 59.85 | 24.74 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.